Physician profile
Calvin E Williams
NPI 1801847322
$1,257.51
in general payments reported to CMS, 2019-2025
11 companies · $730 in 2025
The $730 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $261 · 2024: $267 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,257.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $427.50 | 2025 | Restrata Wound Matrix |
| Viiv Healthcare Company | $213.02 | 2023-2024 | |
| Angiodynamics, INC. | $135.00 | 2023 | Auryon Laser System 100-120 Vac |
| Regeneron Healthcare Solutions, INC. | $132.45 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $102.29 | 2024 | Biktarvy |
| Astrazeneca Pharmaceuticals Lp | $58.27 | 2025 | Tezspire |
| Vertex Pharmaceuticals Incorporated | $55.80 | 2025 | |
| Glaxosmithkline, LLC. | $44.44 | 2025 | Nucala |
| Genzyme Corporation | $38.78 | 2025 | |
| Verona Pharma, INC. | $27.48 | 2025 | Ohtuvayre |
| Organon LLC | $22.48 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.